

## The Rise of Sports Medicine in China: Blending Traditional and Modern Approaches to Enhance Patient Care


### EXECUTIVE SUMMARY

- **Sports medicine is an important segment of orthopaedics, accounting for 11% of the overall orthopaedic market worldwide in 2018**, and it is expected to be one of the fastest-growing segments of that market in the future.

Basically, sports medicine is focused on prevention, diagnosis as well as treatment of sports-related injuries, including sprains, strains, fractures, concussions, dislocation and exercise-induced asthma. In addition, sports medicine also aims to help professional athletes and sports enthusiasts achieve their training goals by offering advice on systematic exercises, nutrition and the use of supplements.

- **Global market size of sports medicine reached US\$6.6 billion in 2019 and is projected to grow at a compound annual growth rate (“CAGR”) of 6% during 2020-2025.** Geographically, North America has the highest market share with the U.S. being the mature and largest market, representing about half of the total market size around the globe.

#### Exhibit A: Global Sports Medicine Market Share by Region in 2019



Source: SiYu Research Institute

The U.S. sports medicine market totalled US\$2.83 billion in 2019, and U.S. market size is forecast to grow over the next five years with a CAGR of 4.1% with the nation’s well-established healthcare infrastructure, relatively high average expenditure on sports injuries, and readily available cutting-edge orthopaedic devices and consumables being the contributing factors for continued growth going forward.

- **As the penetration rates of sports medicine in China, Japan, and South Korea continue to increase, the Asia-Pacific region is becoming the fastest-growing regional market.** Importantly, these countries have relatively more favorable procedures for product approval, which facilitate easy access to advanced products and medical equipment. In addition, medical tourism in the region is expected to revive and further drive market growth after the COVID-19 pandemic has been brought under control amid the rising vaccination rates globally and pent-up demand.

## IMPORTANT DISCLOSURES

---

Cedrus Investments Ltd. (“Cedrus”) does and seeks to do business with companies covered in research reports distributed by Cedrus. Investors should consider this report as only a single factor in making their investment decision.

For additional information, please send an e-mail to [information@cedrusinvestments.com](mailto:information@cedrusinvestments.com)

For private circulation only. This report is prepared by Cedrus and is for informational purposes only and is not intended to be, nor should it be construed to be, an advertisement or an offer or a solicitation of an offer to buy or sell any securities. The information herein, or upon which opinions have been based, has been obtained from sources believed to be reliable, but no representations, express or implied, or guarantees, can be made as to their accuracy, timeliness or completeness. The information and opinions in this report are current as of the date of the report. We do not endeavor to update any changes to the information and opinions in this report. Unless otherwise stated, all views expressed herein (including estimates or forecasts) are solely those of our research department and subject to change without notice.

The information provided in this research report is not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or clearing organization or where Cedrus is not authorized to provide such information.

This report does not take into account the specific investment objectives, financial situation, and the particular needs of any specific company that may receive it. Before acting on any information in this report, readers should consider whether it is suitable for their own particular circumstances and obtain professional advice related to their own investment needs and objectives. The value of securities mentioned in this report and income from them may go up or down, and investors may realize losses on any investments. Past performance is not a guide to future performance. Future terms are not guaranteed, and a loss of original capital may occur.

Neither the analysts responsible for this report nor any related household members are officers, directors, or advisory board members of any covered company. No one at a covered company is on the Board of Directors of Cedrus or its affiliates. The compensation for the analysts who prepare reports is determined exclusively by senior management. Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of Cedrus as a whole, of which investment banking, sales and trading are a part.

Cedrus does engage in investment banking. Cedrus does trade securities on a principal basis; however, Cedrus’ research analysts are prohibited from owning securities they cover through Research Reports.

---

**Copyright 2021 Cedrus Investments Ltd. All rights reserved. Any unauthorized use or disclosure prohibited.**